Top

Published in:

Open Access 01-12-2012 | Case report

Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast

Authors: Nathalie Wurtz, Aurélie Pascual, Adeline Marin-Jauffre, Housem Bouchiba, Nicolas Benoit, Marc Desbordes, Maryse Martelloni, Vincent Pommier de Santi, Georges Richa, Nicolas Taudon, Bruno Pradines, Sébastien Briolant

Published in: Malaria Journal | Issue 1/2012

Abstract

The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone^®) has shown high efficacy against Plasmodium falciparum with only mild side-effects. Treatment failures have been attributed to suboptimal dosages or to parasite resistance resulting from a point mutation in the cytochrome b gene. In this paper, a case of early treatment failure was reported in a patient treated with atovaquone-proguanil; this failure was not associated with a mutation in the parasite cytochrome b gene, with impaired drug bioavailability, or with re-infection.

Boggild AK, Parise ME, Lewis LS, Kain KC: Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). AmJTrop Med Hyg. 2007, 76: 208-223.

Patel SN, Kain KC: Atovaquone-proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther. 2005, 3: 849-861. 10.1586/14787210.3.6.849.CrossRefPubMed

Nakato H, Vivancos R, Hunter PR: A systematic review and meta-analysis of the effectiveness and safety of atovaquone-proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother. 2007, 60: 929-936. 10.1093/jac/dkm337.CrossRefPubMed

Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB: Malarone (atovaquone‐proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg. 1999, 60: 533-541.

Osei-Akoto A, Orton L, Owusu-Ofori SP: Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database Syst Rev. 2005, 2005-CD004529.

Contentin L, Grammatico-Guillon L, Desoubeaux G, Baron S, Thanh HD: Atovaquone-proguanil treatment failure in Plasmodium falciparum. Presse Med. 2011, 40: 1081-1083. 10.1016/j.lpm.2011.03.009.CrossRefPubMed

Durand R, Prendki V, Cailhol J, Hubert V, Ralaimazava P, Massias L, Bouchaud O, Le Bras J: Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Emerg Infect Dis. 2008, 14: 320-322. 10.3201/eid1402.070945.PubMedCentralCrossRefPubMed

Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A: Evidence of Plasmodium falciparum malaria resistant to atovaquone‐proguanil hydrochloride: case reports. BMJ. 2003, 326: 628-629. 10.1136/bmj.326.7390.628.PubMedCentralCrossRefPubMed

Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G: Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos. Nigeria. Malar J. 2002, 1: 1-CrossRefPubMed

10.

Kuhn S, Gill MJ, Kain KC: Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. AmJTrop Med Hyg. 2005, 72: 407-409.

11.

Rose GW, Suh KN, Kain KC, Le Saux N, McCarthy AE: Atovaquone-proguanil resistance in imported falciparum malaria in a young child. Pediatr Infect Dis J. 2008, 27: 567-569. 10.1097/INF.0b013e318167918d.CrossRefPubMed

12.

Schwartz E, Bujanover S, Kain KC: Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003, 37: 450-451. 10.1086/375599.CrossRefPubMed

13.

Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T: Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J. 2004, 3: 14-10.1186/1475-2875-3-14.PubMedCentralCrossRefPubMed

14.

Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B: Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Antimicrob Agents Chemother. 2008, 54: 966-967.CrossRef

15.

Parola P, Pradines B, Simon F, Carlotti MP, Minodier P, Ranjeva MP, Badiaga S, Bertaux L, Delmont J, Morillon M, Silai R, Brouqui P, Parzy D: Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. AmJTrop Med Hyg. 2007, 77: 431-437.

16.

WHO: Evaluation et surveillance de l’efficacité des antipaludiques pour le traitement du paludisme à Plasmodium falciparum non compliqué. 2004, World Health Organization, Geneva, Report No. : WHO/HTM/RBM/2003.50

17.

Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S: Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J. 2011, 10: 336-10.1186/1475-2875-10-336.PubMedCentralCrossRefPubMed

18.

Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J: Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 2006, 8: 2599-2604. 10.1016/j.micinf.2006.07.011.CrossRefPubMed

19.

Pradines B, Dormoire J, Briolant S, Bogreau H, Rogier C: La résistance aux antipaludiques. Rev Fr Lab. 2010, 422: 51-62.

20.

Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B: Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis. 2010, 201: 153-159. 10.1086/648594.CrossRefPubMed

21.

Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, Mosnier J, Amalvict R, Fusai T, Rogier C, Pradines B: Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother. 2009, 53: 1926-1930. 10.1128/AAC.01243-08.PubMedCentralCrossRefPubMed

22.

Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, Pradines B: Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. J Antimicrob Chemother. 2010, 65: 1387-1394. 10.1093/jac/dkq173.CrossRefPubMed

23.

Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C: Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. AmJTrop Med Hyg. 2006, 74: 953-959.

24.

Doudier B, Bogreau H, DeVries A, Poncon N, Stauffer WM, Fontenille D, Rogier C, Parola P: Possible autochthonous malaria from Marseille to Minneapolis. Emerg Infect Dis. 2007, 13: 1236-1238. 10.3201/eid1308.070143.PubMedCentralCrossRefPubMed

25.

Legrand E, Volney B, Lavergne A, Tournegros C, Florent L, Accrombessi D, Guillotte M, Mercereau-Puijalon O, Esterre P: Molecular analysis of two local falciparum malaria outbreaks on the French Guiana Coast confirms the msp1 B-K1/varD genotype association with severe malaria. Malar J. 2005, 4: 26-10.1186/1475-2875-4-26.PubMedCentralCrossRefPubMed

26.

Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, Trumpower BL: Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem. 2005, 280: 17142-17148. 10.1074/jbc.M500388200.CrossRefPubMed

27.

Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997, 272: 3961-3966. 10.1074/jbc.272.7.3961.CrossRefPubMed

28.

Srivastava IK, Vaidya AB: A mechanism for the synergistic antimalarial action of atovaquone‐proguanil. Antimicrob Agents Chemother. 1999, 43: 1334-1339.PubMedCentralPubMed

29.

Vaidya AB, Mather MW: Atovaquone resistance in malaria parasites. Drug Resist Updat. 2000, 3: 283-287. 10.1054/drup.2000.0157.CrossRefPubMed

30.

GlaxoSmithKlineInc: Malarone. GSK Product Monograph Research Triangle Park. 2004, GSK, NC

31.

Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ: Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol. 1996, 42: 589-597.CrossRefPubMed

32.

Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR: A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone-proguanil) for the prophylaxis of malaria in Zambia. AmJTrop Med Hyg. 1999, 60: 521-525.

33.

Hussein Z, Eaves J, Hutchinson DB, Canfield CJ: Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther. 1997, 61: 518-530. 10.1016/S0009-9236(97)90132-6.CrossRefPubMed

34.

Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD: Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. AmJTrop Med Hyg. 2009, 81: 747-753.CrossRef

35.

Gschwend MH, Martin W, Erenmemisoglu A, Scherm M, Dilger C, Tamur U, Kanzik I, Hincal AA: Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. Arzneimittelforschung. 2007, 57: 347-351.PubMed

36.

WHO: Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring : 1996–2004. 2005, World Health Organization, Geneva, Report No.: WHO/HTM/MAL/2005.1103

37.

White NJ: Why is it that antimalarial drug treatments do not always work?. Ann Trop Med Parasitol. 1998, 92: 449-458. 10.1080/00034989859429.CrossRefPubMed

Title: Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast
Authors: Nathalie Wurtz
Aurélie Pascual
Adeline Marin-Jauffre
Housem Bouchiba
Nicolas Benoit
Marc Desbordes
Maryse Martelloni
Vincent Pommier de Santi
Georges Richa
Nicolas Taudon
Bruno Pradines
Sébastien Briolant
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Malaria Journal / Issue 1/2012
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/1475-2875-11-146

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene pfcrt

Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii

Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study

Modelling malaria treatment practices in Bangladesh using spatial statistics

Survey for asymptomatic malaria cases in low transmission settings of Iran under elimination programme

Sub-optimal delivery of intermittent preventive treatment for malaria in pregnancy in Nigeria: influence of provider factors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page